Guidelines of care for the management of acne vulgaris

Open AccessPublished:February 17, 2016DOI:https://doi.org/10.1016/j.jaad.2015.12.037
      Acne is one of the most common disorders treated by dermatologists and other health care providers. While it most often affects adolescents, it is not uncommon in adults and can also be seen in children. This evidence-based guideline addresses important clinical questions that arise in its management. Issues from grading of acne to the topical and systemic management of the disease are reviewed. Suggestions on use are provided based on available evidence.

      Key words

      References

        • Strauss J.S.
        • Krowchuk D.P.
        • Leyden J.J.
        • et al.
        Guidelines of care for acne vulgaris management.
        J Am Acad Dermatol. 2007; 56: 651-663
        • Eichenfield L.F.
        • Krakowski A.C.
        • Piggott C.
        • et al.
        Evidence-based recommendations for the diagnosis and treatment of pediatric acne.
        Pediatrics. 2013; 131: S163-S186
        • Ebell M.H.
        • Siwek J.
        • Weiss B.D.
        • et al.
        Simplifying the language of evidence to improve patient care: Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in medical literature.
        J Fam Pract. 2004; 53: 111-120
      1. American Academy of Dermatology website. Guideline development process. Available at: https://www.aad.org/practice-tools/quality-care/clinical-guidelines/guideline-development-process. Accessed January 4, 2016.

        • White G.M.
        Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris.
        J Am Acad Dermatol. 1998; 39: S34-S37
        • Bhate K.
        • Williams H.C.
        Epidemiology of acne vulgaris.
        Br J Dermatol. 2013; 168: 474-485
        • Goulden V.
        • Stables G.I.
        • Cunliffe W.J.
        Prevalence of facial acne in adults.
        J Am Acad Dermatol. 1999; 41: 577-580
        • Tan J.K.
        • Tang J.
        • Fung K.
        • et al.
        Development and validation of a comprehensive acne severity scale.
        J Cutan Med Surg. 2007; 11: 211-216
        • Mallon E.
        • Newton J.N.
        • Klassen A.
        • et al.
        The quality of life in acne: a comparison with general medical conditions using generic questionnaires.
        Br J Dermatol. 1999; 140: 672-676
        • Gupta M.A.
        • Johnson A.M.
        • Gupta A.K.
        The development of an Acne Quality of Life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris.
        Acta Derm Venereol. 1998; 78: 451-456
        • Lasek R.J.
        • Chren M.M.
        Acne vulgaris and the quality of life of adult dermatology patients.
        Arch Dermatol. 1998; 134: 454-458
        • Martin A.R.
        • Lookingbill D.P.
        • Botek A.
        • et al.
        Health-related quality of life among patients with facial acne—assessment of a new acne-specific questionnaire.
        Clin Exp Dermatol. 2001; 26: 380-385
        • Rapp S.R.
        • Feldman S.R.
        • Graham G.
        • et al.
        The Acne Quality of Life Index (Acne-QOLI): development and validation of a brief instrument.
        Am J Clin Dermatol. 2006; 7: 185-192
        • Dreno B.
        • Khammari A.
        • Orain N.
        • et al.
        ECCA grading scale: an original validated acne scar grading scale for clinical practice in dermatology.
        Dermatology. 2007; 214: 46-51
        • Pochi P.E.
        • Shalita A.R.
        • Strauss J.S.
        • et al.
        Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990.
        J Am Acad Dermatol. 1991; 24: 495-500
        • Doshi A.
        • Zaheer A.
        • Stiller M.J.
        A comparison of current acne grading systems and proposal of a novel system.
        Int J Dermatol. 1997; 36: 416-418
        • Lucky A.W.
        • Barber B.L.
        • Girman C.J.
        • et al.
        A multirater validation study to assess the reliability of acne lesion counting.
        J Am Acad Dermatol. 1996; 35: 559-565
        • Cook C.H.
        • Centner R.L.
        • Michaels S.E.
        An acne grading method using photographic standards.
        Arch Dermatol. 1979; 115: 571-575
        • Burke B.M.
        • Cunliffe W.J.
        The assessment of acne vulgaris–the Leeds technique.
        Br J Dermatol. 1984; 111: 83-92
        • Allen B.S.
        • Smith Jr., J.G.
        Various parameters for grading acne vulgaris.
        Arch Dermatol. 1982; 118: 23-25
        • Dreno B.
        • Poli F.
        • Pawin H.
        • et al.
        Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe.
        J Eur Acad Dermatol Venereol. 2011; 25: 43-48
        • Hayashi N.
        • Akamatsu H.
        • Kawashima M.
        Acne Study Group. Establishment of grading criteria for acne severity.
        J Dermatol. 2008; 35: 255-260
        • Hayashi N.
        • Suh D.H.
        • Akamatsu H.
        • Kawashima M.
        • Acne Study Group
        Evaluation of the newly established acne severity classification among Japanese and Korean dermatologists.
        J Dermatol. 2008; 35: 261-263
        • Tan J.
        • Wolfe B.
        • Weiss J.
        • et al.
        Acne severity grading: determining essential clinical components and features using a Delphi consensus.
        J Am Acad Dermatol. 2012; 67: 187-193
        • Tan J.K.
        • Jones E.
        • Allen E.
        • et al.
        Evaluation of essential clinical components and features of current acne global grading scales.
        J Am Acad Dermatol. 2013; 69: 754-761
        • Beylot C.
        • Chivot M.
        • Faure M.
        • et al.
        Inter-observer agreement on acne severity based on facial photographs.
        J Eur Acad Dermatol Venereol. 2010; 24: 196-198
        • Tan J.K.
        • Fung K.
        • Bulger L.
        Reliability of dermatologists in acne lesion counts and global assessments.
        J Cutan Med Surg. 2006; 10: 160-165
        • Bergman H.
        • Tsai K.Y.
        • Seo S.J.
        • Kvedar J.C.
        • Watson A.J.
        Remote assessment of acne: the use of acne grading tools to evaluate digital skin images.
        Telemed J E Health. 2009; 15: 426-430
        • Min S.
        • Kong H.J.
        • Yoon C.
        • Kim H.C.
        • Suh D.H.
        Development and evaluation of an automatic acne lesion detection program using digital image processing.
        Skin Res Technol. 2013; 19: e423-e432
        • Qureshi A.A.
        • Brandling-Bennett H.A.
        • Giberti S.
        • et al.
        Evaluation of digital skin images submitted by patients who received practical training or an online tutorial.
        J Telemed Telecare. 2006; 12: 79-82
        • Choi C.W.
        • Choi J.W.
        • Park K.C.
        • Youn S.W.
        Ultraviolet-induced red fluorescence of patients with acne reflects regional casual sebum level and acne lesion distribution: qualitative and quantitative analyses of facial fluorescence.
        Br J Dermatol. 2012; 166: 59-66
        • Choi C.W.
        • Lee D.H.
        • Kim H.S.
        • et al.
        The clinical features of late onset acne compared with early onset acne in women.
        J Eur Acad Dermatol Venereol. 2011; 25: 454-461
        • Dobrev H.
        Fluorescence diagnostic imaging in patients with acne.
        Photodermatol Photoimmunol Photomed. 2010; 26: 285-289
        • Choi C.W.
        • Choi J.W.
        • Youn S.W.
        Subjective facial skin type, based on the sebum related symptoms, can reflect the objective casual sebum level in acne patients.
        Skin Res Technol. 2013; 19: 176-182
        • Kim M.K.
        • Choi S.Y.
        • Byun H.J.
        • et al.
        Comparison of sebum secretion, skin type, pH in humans with and without acne.
        Arch Dermatol Res. 2006; 298: 113-119
        • Xhauflaire-Uhoda E.
        • Pierard G.E.
        Skin capacitance imaging of acne lesions.
        Skin Res Technol. 2007; 13: 9-12
        • Youn S.H.
        • Choi C.W.
        • Choi J.W.
        • Youn S.W.
        The skin surface pH and its different influence on the development of acne lesion according to gender and age.
        Skin Res Technol. 2013; 19: 131-136
        • Youn S.W.
        • Kim J.H.
        • Lee J.E.
        • Kim S.O.
        • Park K.C.
        The facial red fluorescence of ultraviolet photography: is this color due to Propionibacterium acnes or the unknown content of secreted sebum?.
        Skin Res Technol. 2009; 15: 230-236
        • Zane C.
        • Capezzera R.
        • Pedretti A.
        • Facchinetti E.
        • Calzavara-Pinton P.
        Non-invasive diagnostic evaluation of phototherapeutic effects of red light phototherapy of acne vulgaris.
        Photodermatol Photoimmunol Photomed. 2008; 24: 244-248
        • Cove J.H.
        • Cunliffe W.J.
        • Holland K.T.
        Acne vulgaris: is the bacterial population size significant?.
        Br J Dermatol. 1980; 102: 277-280
        • Mourelatos K.
        • Eady E.A.
        • Cunliffe W.J.
        • Clark S.M.
        • Cove J.H.
        Temporal changes in sebum excretion and propionibacterial colonization in preadolescent children with and without acne.
        Br J Dermatol. 2007; 156: 22-31
        • Shaheen B.
        • Gonzalez M.
        A microbial aetiology of acne: what is the evidence?.
        Br J Dermatol. 2011; 165: 474-485
        • Fitz-Gibbon S.
        • Tomida S.
        • Chiu B.H.
        • et al.
        Propionibacterium acnes strain populations in the human skin microbiome associated with acne.
        J Invest Dermatol. 2013; 133: 2152-2160
        • Holland C.
        • Mak T.N.
        • Zimny-Arndt U.
        • et al.
        Proteomic identification of secreted proteins of Propionibacterium acnes.
        BMC Microbiol. 2010; 10: 230
        • Lomholt H.B.
        • Kilian M.
        Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne.
        PLoS One. 2010; 5: e12277
        • Miura Y.
        • Ishige I.
        • Soejima N.
        • et al.
        Quantitative PCR of Propionibacterium acnes DNA in samples aspirated from sebaceous follicles on the normal skin of subjects with or without acne.
        J Med Dent Sci. 2010; 57: 65-74
        • Tochio T.
        • Tanaka H.
        • Nakata S.
        • Ikeno H.
        Accumulation of lipid peroxide in the content of comedones may be involved in the progression of comedogenesis and inflammatory changes in comedones.
        J Cosmet Dermatol. 2009; 8: 152-158
        • Tomida S.
        • Nguyen L.
        • Chiu B.H.
        • et al.
        Pan-genome and comparative genome analyses of propionibacterium acnes reveal its genomic diversity in the healthy and diseased human skin microbiome.
        MBio. 2013; 4: e00003-e00013
        • Lucky A.W.
        • Biro F.M.
        • Simbartl L.A.
        • Morrison J.A.
        • Sorg N.W.
        Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study.
        J Pediatr. 1997; 130: 30-39
        • Bunker C.B.
        • Newton J.A.
        • Kilborn J.
        • et al.
        Most women with acne have polycystic ovaries.
        Br J Dermatol. 1989; 121: 675-680
        • Lawrence D.M.
        • Katz M.
        • Robinson T.W.
        • et al.
        Reduced sex hormone binding globulin and derived free testosterone levels in women with severe acne.
        Clin Endocrinol. 1981; 15: 87-91
        • Timpatanapong P.
        • Rojanasakul A.
        Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne.
        J Dermatol. 1997; 24: 223-229
        • Lucky A.W.
        Endocrine aspects of acne.
        Pediatr Clin North Am. 1983; 30: 495-499
        • Lucky A.W.
        • McGuire J.
        • Rosenfield R.L.
        • Lucky P.A.
        • Rich B.H.
        Plasma androgens in women with acne vulgaris.
        J Invest Dermatol. 1983; 81: 70-74
        • Abulnaja K.O.
        Changes in the hormone and lipid profile of obese adolescent Saudi females with acne vulgaris.
        Braz J Med Biol Res. 2009; 42: 501-505
        • Arora M.K.
        • Seth S.
        • Dayal S.
        The relationship of lipid profile and menstrual cycle with acne vulgaris.
        Clin Biochem. 2010; 43: 1415-1420
        • Fyrand O.
        • Jakobsen H.B.
        Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris.
        Dermatologica. 1986; 172: 263-267
        • Mills Jr., O.H.
        • Kligman A.M.
        • Pochi P.
        • Comite H.
        Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris.
        Int J Dermatol. 1986; 25: 664-667
        • Schutte H.
        • Cunliffe W.J.
        • Forster R.A.
        The short-term effects of benzoyl peroxide lotion on the resolution of inflamed acne lesions.
        Br J Dermatol. 1982; 106: 91-94
        • Mills Jr., O.
        • Thornsberry C.
        • Cardin C.W.
        • Smiles K.A.
        • Leyden J.J.
        Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle.
        Acta Derm Venereol. 2002; 82: 260-265
        • Bernstein J.E.
        • Shalita A.R.
        Topically applied erythromycin in inflammatory acne vulgaris.
        J Am Acad Dermatol. 1980; 2: 318-321
        • Jones E.L.
        • Crumley A.F.
        Topical erythromycin vs blank vehicle in a multiclinic acne study.
        Arch Dermatol. 1981; 117: 551-553
        • Shalita A.R.
        • Smith E.B.
        • Bauer E.
        Topical erythromycin v clindamycin therapy for acne. A multicenter, double-blind comparison.
        Arch Dermatol. 1984; 120: 351-355
        • Leyden J.J.
        • Shalita A.R.
        • Saatjian G.D.
        • Sefton J.
        Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris.
        J Am Acad Dermatol. 1987; 16: 822-827
        • Kuhlman D.S.
        • Callen J.P.
        A comparison of clindamycin phosphate 1 percent topical lotion and placebo in the treatment of acne vulgaris.
        Cutis. 1986; 38: 203-206
        • Becker L.E.
        • Bergstresser P.R.
        • Whiting D.A.
        • et al.
        Topical clindamycin therapy for acne vulgaris. A cooperative clinical study.
        Arch Dermatol. 1981; 117: 482-485
        • Leyden J.J.
        • Hickman J.G.
        • Jarratt M.T.
        • Stewart D.M.
        • Levy S.F.
        The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product.
        J Cutan Med Surg. 2001; 5: 37-42
        • Lookingbill D.P.
        • Chalker D.K.
        • Lindholm J.S.
        • et al.
        Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations.
        J Am Acad Dermatol. 1997; 37: 590-595
        • Tschen E.H.
        • Katz H.I.
        • Jones T.M.
        • et al.
        A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris.
        Cutis. 2001; 67: 165-169
        • Krishnan G.
        Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris.
        Practitioner. 1976; 216: 106-109
        • Bradford L.G.
        • Montes L.F.
        Topical application of vitamin A acid in acne vulgaris.
        South Med J. 1974; 67: 683-687
        • Shalita A.R.
        • Chalker D.K.
        • Griffith R.F.
        • et al.
        Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
        Cutis. 1999; 63: 349-354
        • Shalita A.
        • Weiss J.S.
        • Chalker D.K.
        • et al.
        A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial.
        J Am Acad Dermatol. 1996; 34: 482-485
        • Cunliffe W.J.
        • Caputo R.
        • Dreno B.
        • et al.
        Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials.
        J Am Acad Dermatol. 1997; 36: S126-S134
        • Richter J.R.
        • Bousema M.T.
        • De Boulle K.L.V.
        • Degreef H.J.
        • Poli F.
        Efficacy of a fixed clindamycin phosphate 1.2%, tretinoin 0.025% gel formulation (Velac) in the topical control of facial acne lesions.
        J Dermatolog Treat. 1998; 9: 81-90
        • Zouboulis C.C.
        • Derumeaux L.
        • Decroix J.
        • Maciejewska-Udziela B.
        • Cambazard F.
        • Stuhlert A.
        A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris.
        Br J Dermatol. 2000; 143: 498-505
        • Christiansen J.V.
        • Gadborg E.
        • Ludvigsen K.
        • et al.
        Topical tretinoin, vitamin A acid (Airol) in acne vulgaris. A controlled clinical trial.
        Dermatologica. 1974; 148: 82-89
        • Dunlap F.E.
        • Mills O.H.
        • Tuley M.R.
        • Baker M.D.
        • Plott R.T.
        Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference.
        Br J Dermatol. 1998; 139: 17-22
        • Kakita L.
        Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris.
        J Am Acad Dermatol. 2000; 43: S51-S54
        • Webster G.F.
        • Berson D.
        • Stein L.F.
        • Fivenson D.P.
        • Tanghetti E.A.
        • Ling M.
        Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial.
        Cutis. 2001; 67: 4-9
        • Galvin S.A.
        • Gilbert R.
        • Baker M.
        • Guibal F.
        • Tuley M.R.
        Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations.
        Br J Dermatol. 1998; 139: 34-40
        • Cunliffe W.J.
        • Holland K.T.
        Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne.
        Acta Derm Venereol Suppl (Stockh). 1989; 143: 31-34
        • Katsambas A.
        • Graupe K.
        • Stratigos J.
        Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin.
        Acta Derm Venereol Suppl (Stockh). 1989; 143: 35-39
        • Draelos Z.D.
        • Carter E.
        • Maloney J.M.
        • et al.
        Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.
        J Am Acad Dermatol. 2007; 56: 439.e1-439.e10
        • Lucky A.W.
        • Maloney J.M.
        • Roberts J.
        • et al.
        Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.
        J Drugs Dermatol. 2007; 6: 981-987
        • Tanghetti E.
        • Harper J.C.
        • Oefelein M.G.
        The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable.
        J Drugs Dermatol. 2012; 11: 1417-1421
        • Shalita A.R.
        Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle.
        Cutis. 1981; 28 (561): 556-558
        • Garner S.E.
        • Eady A.
        • Bennett C.
        • Newton J.N.
        • Thomas K.
        • Popescu C.M.
        Minocycline for acne vulgaris: efficacy and safety.
        Cochrane Database Syst Rev. 2012; : CD002086
        • Leyden J.J.
        • Bruce S.
        • Lee C.S.
        • et al.
        A randomized, phase 2, dose-ranging study in the treatment of moderate to severe inflammatory facial acne vulgaris with doxycycline calcium.
        J Drugs Dermatol. 2013; 12: 658-663
        • Lebrun-Vignes B.
        • Kreft-Jais C.
        • Castot A.
        • Chosidow O.
        • French Network of Regional Centers of Pharmacovigilance
        Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature.
        Br J Dermatol. 2012; 166: 1333-1341
        • Kermani T.A.
        • Ham E.K.
        • Camilleri M.J.
        • Warrington K.J.
        Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series.
        Semin Arthritis Rheum. 2012; 42: 213-221
        • Rafiei R.
        • Yaghoobi R.
        Azithromycin versus tetracycline in the treatment of acne vulgaris.
        J Dermatolog Treat. 2006; 17: 217-221
        • Jen I.
        A comparison of low dosage trimethoprim/sulfamethoxazole with oxytetracycline in acne vulgaris.
        Cutis. 1980; 26: 106-108
        • Fenner J.A.
        • Wiss K.
        • Levin N.A.
        Oral cephalexin for acne vulgaris: clinical experience with 93 patients.
        Pediatr Dermatol. 2008; 25: 179-183
        • Gold L.S.
        • Cruz A.
        • Eichenfield L.
        • et al.
        Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg.
        Cutis. 2010; 85: 94-104
        • Leyden J.
        • Thiboutot D.M.
        • Shalita A.R.
        • et al.
        Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
        Arch Dermatol. 2006; 142: 605-612
        • Margolis D.J.
        • Fanelli M.
        • Hoffstad O.
        • Lewis J.D.
        Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease.
        Am J Gastroenterol. 2010; 105: 2610-2616
        • Lucky A.W.
        • Koltun W.
        • Thiboutot D.
        • et al.
        A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
        Cutis. 2008; 82: 143-150
        • Maloney J.M.
        • Dietze Jr., P.
        • Watson D.
        • et al.
        Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
        Obstet Gynecol. 2008; 112: 773-781
        • Maloney J.M.
        • Dietze Jr., P.
        • Watson D.
        • et al.
        A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
        J Drugs Dermatol. 2009; 8: 837-844
        • Plewig G.
        • Cunliffe W.J.
        • Binder N.
        • Hoschen K.
        Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial.
        Contraception. 2009; 80: 25-33
        • Shaw J.C.
        Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients.
        J Am Acad Dermatol. 2000; 43: 498-502
        • Sato K.
        • Matsumoto D.
        • Iizuka F.
        • et al.
        Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians.
        Aesthetic Plast Surg. 2006; 30: 689-694
        • Wang H.S.
        • Wang T.H.
        • Soong Y.K.
        Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea.
        Changgeng Yi Xue Za Zhi. 1999; 22: 423-432
        • Castelo-Branco C.
        • Moyano D.
        • Gomez O.
        • Balasch J.
        Long-term safety and tolerability of flutamide for the treatment of hirsutism.
        Fertil Steril. 2009; 91: 1183-1188
        • Nader S.
        • Rodriguez-Rigau L.J.
        • Smith K.D.
        • Steinberger E.
        Acne and hyperandrogenism: impact of lowering androgen levels with glucocorticoid treatment.
        J Am Acad Dermatol. 1984; 11: 256-259
        • Amichai B.
        • Shemer A.
        • Grunwald M.H.
        Low-dose isotretinoin in the treatment of acne vulgaris.
        J Am Acad Dermatol. 2006; 54: 644-646
        • Goldstein J.A.
        • Socha-Szott A.
        • Thomsen R.J.
        • Pochi P.E.
        • Shalita A.R.
        • Strauss J.S.
        Comparative effect of isotretinoin and etretinate on acne and sebaceous gland secretion.
        J Am Acad Dermatol. 1982; 6: 760-765
        • Jones D.H.
        • King K.
        • Miller A.J.
        • Cunliffe W.J.
        A dose-response study of I3-cis-retinoic acid in acne vulgaris.
        Br J Dermatol. 1983; 108: 333-343
        • Layton A.M.
        • Knaggs H.
        • Taylor J.
        • Cunliffe W.J.
        Isotretinoin for acne vulgaris–10 years later: a safe and successful treatment.
        Br J Dermatol. 1993; 129: 292-296
        • Lehucher-Ceyrac D.
        • Weber-Buisset M.J.
        Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years.
        Dermatology. 1993; 186: 123-128
        • Peck G.L.
        • Olsen T.G.
        • Butkus D.
        • et al.
        Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study.
        J Am Acad Dermatol. 1982; 6: 735-745
        • Rubinow D.R.
        • Peck G.L.
        • Squillace K.M.
        • Gantt G.G.
        Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin.
        J Am Acad Dermatol. 1987; 17: 25-32
        • Stainforth J.M.
        • Layton A.M.
        • Taylor J.P.
        • Cunliffe W.J.
        Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course?.
        Br J Dermatol. 1993; 129: 297-301
        • Strauss J.S.
        • Leyden J.J.
        • Lucky A.W.
        • et al.
        A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne.
        J Am Acad Dermatol. 2001; 45: 187-195
        • Strauss J.S.
        • Rapini R.P.
        • Shalita A.R.
        • et al.
        Isotretinoin therapy for acne: results of a multicenter dose-response study.
        J Am Acad Dermatol. 1984; 10: 490-496
        • Strauss J.S.
        • Stranieri A.M.
        Changes in long-term sebum production from isotretinoin therapy.
        J Am Acad Dermatol. 1982; 6: 751-756
        • Goldsmith L.A.
        • Bolognia J.L.
        • Callen J.P.
        • et al.
        American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations.
        J Am Acad Dermatol. 2004; 50: 900-906
        • Lehucher-Ceyrac D.
        • de La Salmoniere P.
        • Chastang C.
        • Morel P.
        Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients.
        Dermatology. 1999; 198: 278-283
        • Strauss J.S.
        • Leyden J.J.
        • Lucky A.W.
        • et al.
        Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin.
        J Am Acad Dermatol. 2001; 45: 196-207
        • Webster G.F.
        • Leyden J.J.
        • Gross J.A.
        Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study.
        J Am Acad Dermatol. 2013; 69: 762-767
        • Alhusayen R.O.
        • Juurlink D.N.
        • Mamdani M.M.
        • Morrow R.L.
        • Shear N.H.
        • Dormuth C.R.
        Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.
        J Invest Dermatol. 2013; 133: 907-912
        • Crockett S.D.
        • Gulati A.
        • Sandler R.S.
        • Kappelman M.D.
        A causal association between isotretinoin and inflammatory bowel disease has yet to be established.
        Am J Gastroenterol. 2009; 104: 2387-2393
        • Crockett S.D.
        • Porter C.Q.
        • Martin C.F.
        • Sandler R.S.
        • Kappelman M.D.
        Isotretinoin use and the risk of inflammatory bowel disease: a case-control study.
        Am J Gastroenterol. 2010; 105: 1986-1993
        • Etminan M.
        • Bird S.T.
        • Delaney J.A.
        • Bressler B.
        • Brophy J.M.
        Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data.
        JAMA Dermatol. 2013; 149: 216-220
        • Reddy D.
        • Siegel C.A.
        • Sands B.E.
        • Kane S.
        Possible association between isotretinoin and inflammatory bowel disease.
        Am J Gastroenterol. 2006; 101: 1569-1573
        • Sundstrom A.
        • Alfredsson L.
        • Sjolin-Forsberg G.
        • Gerden B.
        • Bergman U.
        • Jokinen J.
        Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study.
        BMJ. 2010; 341: c5812
        • Bozdag K.E.
        • Gulseren S.
        • Guven F.
        • Cam B.
        Evaluation of depressive symptoms in acne patients treated with isotretinoin.
        J Dermatolog Treat. 2009; 20: 293-296
        • Chia C.Y.
        • Lane W.
        • Chibnall J.
        • Allen A.
        • Siegfried E.
        Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study.
        Arch Dermatol. 2005; 141: 557-560
        • Cohen J.
        • Adams S.
        • Patten S.
        No association found between patients receiving isotretinoin for acne and the development of depression in a Canadian prospective cohort.
        Can J Clin Pharmacol. 2007; 14: e227-e233
        • Jick S.S.
        • Kremers H.M.
        • Vasilakis-Scaramozza C.
        Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide.
        Arch Dermatol. 2000; 136: 1231-1236
        • Nevoralova Z.
        • Dvorakova D.
        Mood changes, depression and suicide risk during isotretinoin treatment: a prospective study.
        Int J Dermatol. 2013; 52: 163-168
        • Rehn L.M.
        • Meririnne E.
        • Hook-Nikanne J.
        • Isometsa E.
        • Henriksson M.
        Depressive symptoms and suicidal ideation during isotretinoin treatment: a 12-week follow-up study of male Finnish military conscripts.
        J Eur Acad Dermatol Venereol. 2009; 23: 1294-1297
        • Agarwal U.S.
        • Besarwal R.K.
        • Bhola K.
        Oral isotretinoin in different dose regimens for acne vulgaris: a randomized comparative trial.
        Indian J Dermatol Venereol Leprol. 2011; 77: 688-694
        • Akman A.
        • Durusoy C.
        • Senturk M.
        • Koc C.K.
        • Soyturk D.
        • Alpsoy E.
        Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study.
        Arch Dermatol Res. 2007; 299: 467-473
        • Borghi A.
        • Mantovani L.
        • Minghetti S.
        • Giari S.
        • Virgili A.
        • Bettoli V.
        Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission.
        J Eur Acad Dermatol Venereol. 2011; 25: 1094-1098
        • Kaymak Y.
        • Ilter N.
        The effectiveness of intermittent isotretinoin treatment in mild or moderate acne.
        J Eur Acad Dermatol Venereol. 2006; 20: 1256-1260
        • Lee J.W.
        • Yoo K.H.
        • Park K.Y.
        • et al.
        Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study.
        Br J Dermatol. 2011; 164: 1369-1375
        • Leachman S.A.
        • Insogna K.L.
        • Katz L.
        • Ellison A.
        • Milstone L.M.
        Bone densities in patients receiving isotretinoin for cystic acne.
        Arch Dermatol. 1999; 135: 961-965
        • Bershad S.
        • Rubinstein A.
        • Paterniti J.R.
        • et al.
        Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne.
        N Engl J Med. 1985; 313: 981-985
        • De Marchi M.A.
        • Maranhao R.C.
        • Brandizzi L.I.
        • Souza D.R.
        Effects of isotretinoin on the metabolism of triglyceride-rich lipoproteins and on the lipid profile in patients with acne.
        Arch Dermatol Res. 2006; 297: 403-408
        • Zech L.A.
        • Gross E.G.
        • Peck G.L.
        • Brewer H.B.
        Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study.
        Arch Dermatol. 1983; 119: 987-993
        • Shin J.
        • Cheetham T.C.
        • Wong L.
        • et al.
        The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system.
        J Am Acad Dermatol. 2011; 65: 1117-1125
        • Collins M.K.
        • Moreau J.F.
        • Opel D.
        • et al.
        Compliance with pregnancy prevention measures during isotretinoin therapy.
        J Am Acad Dermatol. 2014; 70: 55-59
        • Grover C.
        • Reddu B.S.
        The therapeutic value of glycolic acid peels in dermatology.
        Indian J Dermatol Venereol Leprol. 2003; 69: 148-150
        • Dreno B.
        • Fischer T.C.
        • Perosino E.
        • et al.
        Expert opinion: efficacy of superficial chemical peels in active acne management—what can we learn from the literature today? Evidence-based recommendations.
        J Eur Acad Dermatol Venereol. 2011; 25: 695-704
        • Ilknur T.
        • Demirtasoglu M.
        • Bicak M.U.
        • Ozkan S.
        Glycolic acid peels versus amino fruit acid peels for acne.
        J Cosmet Laser Ther. 2010; 12: 242-245
        • Levine R.M.
        • Rasmussen J.E.
        Intralesional corticosteroids in the treatment of nodulocystic acne.
        Arch Dermatol. 1983; 119: 480-481
        • Potter R.A.
        Intralesional triamcinolone and adrenal suppression in acne vulgaris.
        J Invest Dermatol. 1971; 57: 364-370
        • Bassett I.B.
        • Pannowitz D.L.
        • Barnetson R.S.
        A comparative study of tea-tree oil versus benzoylperoxide in the treatment of acne.
        Med J Aust. 1990; 153: 455-458
        • Enshaieh S.
        • Jooya A.
        • Siadat A.H.
        • Iraji F.
        The efficacy of 5% topical tea tree oil gel in mild to moderate acne vulgaris: a randomized, double-blind placebo-controlled study.
        Indian J Dermatol Venereol Leprol. 2007; 73: 22-25
        • Fouladi R.F.
        Aqueous extract of dried fruit of Berberis vulgaris L. in acne vulgaris, a clinical trial.
        J Diet Suppl. 2012; 9: 253-261
        • Hunt M.J.
        • Barnetson R.S.
        A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne.
        Australas J Dermatol. 1992; 33: 131-134
        • Lalla J.K.
        • Nandedkar S.Y.
        • Paranjape M.H.
        • Talreja N.B.
        Clinical trials of ayurvedic formulations in the treatment of acne vulgaris.
        J Ethnopharmacol. 2001; 78: 99-102
        • Paranjpe P.
        • Kulkarni P.H.
        Comparative efficacy of four Ayurvedic formulations in the treatment of acne vulgaris: a double-blind randomised placebo-controlled clinical evaluation.
        J Ethnopharmacol. 1995; 49: 127-132
        • Hughes H.
        • Brown B.W.
        • Lawlis G.F.
        • Fulton Jr., J.E.
        Treatment of acne vulgaris by biofeedback relaxation and cognitive imagery.
        J Psychosom Res. 1983; 27: 185-191
        • Smith R.N.
        • Mann N.J.
        • Braue A.
        • Makelainen H.
        • Varigos G.A.
        The effect of a high-protein, low glycemic-load diet versus a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial.
        J Am Acad Dermatol. 2007; 57: 247-256
        • Kwon H.H.
        • Yoon J.Y.
        • Hong J.S.
        • Jung J.Y.
        • Park M.S.
        • Suh D.H.
        Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial.
        Acta Derm Venereol. 2012; 92: 241-246
        • Smith R.
        • Mann N.
        • Makelainen H.
        • Roper J.
        • Braue A.
        • Varigos G.
        A pilot study to determine the short-term effects of a low glycemic load diet on hormonal markers of acne: a nonrandomized, parallel, controlled feeding trial.
        Mol Nutr Food Res. 2008; 52: 718-726
        • Preneau S.
        • Dessinioti C.
        • Nguyen J.M.
        • Katsambas A.
        • Dreno B.
        Predictive markers of response to isotretinoin in female acne.
        Eur J Dermatol. 2013; 23: 478-486
        • Ismail N.H.
        • Manaf Z.A.
        • Azizan N.Z.
        High glycemic load diet, milk and ice cream consumption are related to acne vulgaris in Malaysian young adults: a case control study.
        BMC Dermatol. 2012; 12: 13
        • Adebamowo C.A.
        • Spiegelman D.
        • Berkey C.S.
        • et al.
        Milk consumption and acne in adolescent girls.
        Dermatol Online J. 2006; 12: 1
        • Adebamowo C.A.
        • Spiegelman D.
        • Berkey C.S.
        • et al.
        Milk consumption and acne in teenaged boys.
        J Am Acad Dermatol. 2008; 58: 787-793
        • Di Landro A.
        • Cazzaniga S.
        • Parazzini F.
        • et al.
        Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults.
        J Am Acad Dermatol. 2012; 67: 1129-1135
        • Seirafi H.
        • Farnaghi F.
        • Vasheghani-Farahani A.
        • et al.
        Assessment of androgens in women with adult-onset acne.
        Int J Dermatol. 2007; 46: 1188-1191
        • Degitz K.
        • Placzek M.
        • Arnold B.
        • Schmidt H.
        • Plewig G.
        Congenital adrenal hyperplasia and acne in male patients.
        Br J Dermatol. 2003; 148: 1263-1266
        • Trapp C.M.
        • Oberfield S.E.
        Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update.
        Steroids. 2012; 77: 342-346
        • Legro R.S.
        • Arslanian S.A.
        • Ehrmann D.A.
        • et al.
        Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2013; 98: 4565-4592
        • Saleh B.O.
        Role of growth hormone and insulin-like growth factor-I in hyperandrogenism and the severity of acne vulgaris in young males.
        Saudi Med J. 2012; 33: 1196-1200
        • Del Prete M.
        • Mauriello M.C.
        • Faggiano A.
        • et al.
        Insulin resistance and acne: a new risk factor for men?.
        Endocrine. 2012; 42: 555-560
        • Cunliffe W.J.
        • Dodman B.
        • Ead R.
        Benzoyl peroxide in acne.
        Practitioner. 1978; 220: 479-482
        • Fulton Jr., J.E.
        • Farzad-Bakshandeh A.
        • Bradley S.
        Studies on the mechanism of action to topical benzoyl peroxide and vitamin A acid in acne vulgaris.
        J Cutan Pathol. 1974; 1: 191-200
        • Padilla R.S.
        • McCabe J.M.
        • Becker L.E.
        Topical tetracycline hydrochloride vs. topical clindamycin phosphate in the treatment of acne: a comparative study.
        Int J Dermatol. 1981; 20: 445-448
        • Pariser D.M.
        • Rich P.
        • Cook-Bolden F.E.
        • Korotzer A.
        An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris.
        J Drugs Dermatol. 2014; 13: 1083-1089
        • Lucky A.W.
        • Cullen S.I.
        • Funicella T.
        • et al.
        Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris.
        J Am Acad Dermatol. 1998; 38: S24-S30
        • Dreno B.
        • Bettoli V.
        • Ochsendorf F.
        • et al.
        Efficacy and safety of clindamycin phosphate 1.2%/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double-blind, parallel-group, phase III studies.
        Eur J Dermatol. 2014; 24: 201-209
        • Pedace F.J.
        • Stoughton R.
        Topical retinoic acid in acne vulgaris.
        Br J Dermatol. 1971; 84: 465-469
        • Kircik L.H.
        Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study.
        J Drugs Dermatol. 2011; 10: 586-590
        • Del Rosso J.Q.
        • Kircik L.
        • Gallagher C.J.
        Comparative efficacy and tolerability of dapsone 5% gel in adult versus adolescent females with acne vulgaris.
        J Clin Aesthet Dermatol. 2015; 8: 31-37
        • Shalita A.R.
        Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris.
        Clin Ther. 1989; 11: 264-267
        • Elstein W.
        Topical deodorized polysulfides. Broadscope acne therapy.
        Cutis. 1981; 28: 468-472
        • Hurley H.J.
        • Shelley W.B.
        Special topical approach to the treatment of acne. Suppression of sweating with aluminum chloride in an anhydrous formulation.
        Cutis. 1978; 22: 696-703
        • Hjorth N.
        • Storm D.
        • Dela K.
        Topical anhydrous aluminum chloride formulation in the treatment of acne vulgaris: a double-blind study.
        Cutis. 1985; 35: 499-500
        • Bojar R.A.
        • Eady E.A.
        • Jones C.E.
        • Cunliffe W.J.
        • Holland K.T.
        Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc.
        Br J Dermatol. 1994; 130: 329-336
        • Cochran R.J.
        • Tucker S.B.
        • Flannigan S.A.
        Topical zinc therapy for acne vulgaris.
        Int J Dermatol. 1985; 24: 188-190
        • Stainforth J.
        • MacDonald-Hull S.
        • Papworth-Smith J.W.
        • Eady E.A.
        • Cunliffe W.J.
        • Norris J.F.B.
        A single-blind comparison of topical erythromycin/zinc lotion and oral minocycline in the treatment of acne vulgaris.
        J Dermatolog Treat. 1993; 4: 119-122
        • Lebrun C.M.
        Rosac cream with sunscreens (sodium sulfacetamide 10% and sulfur 5%).
        Skinmed. 2004; 3: 92
        • Tarimci N.
        • Sener S.
        • Kilinc T.
        Topical sodium sulfacetamide/sulfur lotion.
        J Clin Pharm Ther. 1997; 22: 301
        • Thiboutot D.
        New treatments and therapeutic strategies for acne.
        Arch Fam Med. 2000; 9: 179-187
        • Shalita A.R.
        • Smith J.G.
        • Parish L.C.
        • Sofman M.S.
        • Chalker D.K.
        Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris.
        Int J Dermatol. 1995; 34: 434-437
        • Khodaeiani E.
        • Fouladi R.F.
        • Amirnia M.
        • Saeidi M.
        • Karimi E.R.
        Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris.
        Int J Dermatol. 2013; 52: 999-1004
        • Tan J.
        • Humphrey S.
        • Vender R.
        • et al.
        A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin.
        Br J Dermatol. 2014; 171: 1508-1516
        • Zaenglein A.L.
        • Shamban A.
        • Webster G.
        • et al.
        A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris.
        J Drugs Dermatol. 2013; 12: 619-625
        • Fleischer Jr., A.B.
        • Dinehart S.
        • Stough D.
        • et al.
        Safety and efficacy of a new extended-release formulation of minocycline.
        Cutis. 2006; 78: 21-31
        • Toossi P.
        • Farshchian M.
        • Malekzad F.
        • Mohtasham N.
        • Kimyai-Asadi A.
        Subantimicrobial-dose doxycycline in the treatment of moderate facial acne.
        J Drugs Dermatol. 2008; 7: 1149-1152
        • Moore A.
        • Ling M.
        • Bucko A.
        • Manna V.
        • Rueda M.J.
        Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40 mg versus doxycycline 100 mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, double-blinded, controlled study.
        J Drugs Dermatol. 2015; 14: 581-586
        • Maleszka R.
        • Turek-Urasinska K.
        • Oremus M.
        • Vukovic J.
        • Barsic B.
        Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris: a randomized, double-blind, noninferiority study.
        Skinmed. 2011; 9: 86-94
        • Antonio J.R.
        • Pegas J.R.
        • Cestari T.F.
        • Do Nascimento L.V.
        Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety.
        J Dermatolog Treat. 2008; 19: 210-215
        • Innocenzi D.
        • Skroza N.
        • Ruggiero A.
        • et al.
        Moderate acne vulgaris: efficacy, tolerance and compliance of oral azithromycin thrice weekly for.
        Acta Dermatovenerol Croat. 2008; 16: 13-18
        • Bardazzi F.
        • Savoia F.
        • Parente G.
        • et al.
        Azithromycin: a new therapeutical strategy for acne in adolescents.
        Dermatol Online J. 2007; 13: 4
        • Basta-Juzbasic A.
        • Lipozencic J.
        • Oremovic L.
        • et al.
        A dose-finding study of azithromycin in the treatment of acne vulgaris.
        Acta Dermatovenerol Croat. 2007; 15: 141-147
        • Kus S.
        • Yucelten D.
        • Aytug A.
        Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris.
        Clin Exp Dermatol. 2005; 30: 215-220
        • Parsad D.
        • Pandhi R.
        • Nagpal R.
        • Negi K.S.
        Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris.
        J Dermatol. 2001; 28: 1-4
        • Gruber F.
        • Grubisic-Greblo H.
        • Kastelan M.
        • et al.
        Azithromycin compared with minocycline in the treatment of acne comedonica and papulo-pustulosa.
        J Chemother. 1998; 10: 469-473
        • Ullah G.
        • Noor S.M.
        • Bhatti Z.
        • Ahmad M.
        • Bangash A.R.
        Comparison of oral azithromycin with oral doxycycline in the treatment of acne vulgaris.
        J Ayub Med Coll Abbottabad. 2014; 26: 64-67
        • Shaughnessy K.K.
        • Bouchard S.M.
        • Mohr M.R.
        • Herre J.M.
        • Salkey K.S.
        Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis.
        J Am Acad Dermatol. 2010; 62: 315-318
        • Smith K.
        • Leyden J.J.
        Safety of doxycycline and minocycline: a systematic review.
        Clin Ther. 2005; 27: 1329-1342
        • Tripathi S.V.
        • Gustafson C.J.
        • Huang K.E.
        • Feldman S.R.
        Side effects of common acne treatments.
        Exp Opin Drug Saf. 2013; 12: 39-51
        • Weinstein M.
        • Laxer R.
        • Debosz J.
        • Somers G.
        Doxycycline-induced cutaneous inflammation with systemic symptoms in a patient with acne vulgaris.
        J Cutan Med Surg. 2013; 17: 283-286
        • Firoz B.F.
        • Henning J.S.
        • Zarzabal L.A.
        • Pollock B.H.
        Toxic epidermal necrolysis: five years of treatment experience from a burn unit.
        J Am Acad Dermatol. 2012; 67: 630-635
        • Roujeau J.C.
        • Kelly J.P.
        • Naldi L.
        • et al.
        Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
        N Engl J Med. 1995; 333: 1600-1607
        • Thiboutot D.M.
        • Shalita A.R.
        • Yamauchi P.S.
        • et al.
        Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study.
        Arch Dermatol. 2006; 142: 597-602
        • Poulin Y.
        • Sanchez N.P.
        • Bucko A.
        • et al.
        A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial.
        Br J Dermatol. 2011; 164: 1376-1382
        • Tan J.
        • Stein Gold L.
        • Schlessinger J.
        • et al.
        Short-term combination therapy and long-term relapse prevention in the treatment of severe acne vulgaris.
        J Drugs Dermatol. 2012; 11: 174-180
        • Moon S.H.
        • Roh H.S.
        • Kim Y.H.
        • et al.
        Antibiotic resistance of microbial strains isolated from Korean acne patients.
        J Dermatol. 2012; 39: 833-837
        • Margolis D.J.
        • Fanelli M.
        • Kupperman E.
        • et al.
        Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study.
        Arch Dermatol. 2012; 148: 326-332
        • Bartlett J.G.
        • Chang T.W.
        • Gurwith M.
        • Gorbach S.L.
        • Onderdonk A.B.
        Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.
        N Engl J Med. 1978; 298: 531-534
        • Carroll K.C.
        • Bartlett J.G.
        Biology of Clostridium difficile: implications for epidemiology and diagnosis.
        Annu Rev Microbiol. 2011; 65: 501-521
        • Arrington E.A.
        • Patel N.S.
        • Gerancher K.
        • Feldman S.R.
        Combined oral contraceptives for the treatment of acne: a practical guide.
        Cutis. 2012; 90: 83-90
        • Davtyan C.
        Four generations of progestins in oral contraceptives.
        Proceedings of UCLA Healthcare. 2012; 16 (Available at:) (Accessed January 5, 2016)
        • Arowojolu A.O.
        • Gallo M.F.
        • Lopez L.M.
        • Grimes D.A.
        Combined oral contraceptive pills for treatment of acne.
        Cochrane Database Syst Rev. 2012; : CD004425
        • Harper J.C.
        Should dermatologists prescribe hormonal contraceptives for acne?.
        Dermatol Ther. 2009; 22: 452-457
        • Rabe T.
        • Kowald A.
        • Ortmann J.
        • Rehberger-Schneider S.
        Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro.
        Gynecol Endocrinol. 2000; 14: 223-230
        • Koltun W.
        • Lucky A.W.
        • Thiboutot D.
        • et al.
        Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
        Contraception. 2008; 77: 249-256
        • Koltun W.
        • Maloney J.M.
        • Marr J.
        • Kunz M.
        Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mug plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis.
        Eur J Obstet Gynecol Reprod Biol. 2011; 155: 171-175
        • Jaisamrarn U.
        • Chaovisitsaree S.
        • Angsuwathana S.
        • Nerapusee O.
        A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial.
        Contraception. 2014; 90: 535-541
        • Palli M.B.
        • Reyes-Habito C.M.
        • Lima X.T.
        • Kimball A.B.
        A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
        J Drugs Dermatol. 2013; 12: 633-637
        • George R.
        • Clarke S.
        • Thiboutot D.
        Hormonal therapy for acne.
        Semin Cutan Med Surg. 2008; 27: 188-196
      2. The American College of Obstetricians and Gynecologists website. Committee opinion 540. Risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills. Available at: http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Risk-of-Venous-Thromboembolism. Accessed January 6, 2016.

      3. US Food and Drug Administration website. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf. Accessed January 6, 2016.

      4. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
        Lancet. 1997; 349: 1202-1209
        • Katsambas A.D.
        • Dessinioti C.
        Hormonal therapy for acne: why not as first line therapy? facts and controversies.
        Clin Dermatol. 2010; 28: 17-23
      5. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.
        Lancet. 1997; 350: 1047-1059
        • Gierisch J.M.
        • Coeytaux R.R.
        • Urrutia R.P.
        • et al.
        Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.
        Cancer Epidemiol Biomarkers Prev. 2013; 22: 1931-1943
        • Appleby P.
        • Beral V.
        • Berrington de González A.
        • et al.
        • International Collaboration of Epidemiological Studies of Cervical Cancer
        Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.
        Lancet. 2007; 370: 1609-1621
        • Lloyd T.
        • Rollings N.
        • Andon M.B.
        • et al.
        Determinants of bone density in young women. I. Relationships among pubertal development, total body bone mass, and total body bone density in premenarchal females.
        J Clin Endocrinol Metab. 1992; 75: 383-387
        • Cromer B.A.
        • Bonny A.E.
        • Stager M.
        • et al.
        Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study.
        Fertil Steril. 2008; 90: 2060-2067
        • Lloyd T.
        • Petit M.A.
        • Lin H.M.
        • Beck T.J.
        Lifestyle factors and the development of bone mass and bone strength in young women.
        J Pediatr. 2004; 144: 776-782
        • Maguire K.
        • Westhoff C.
        The state of hormonal contraception today: established and emerging noncontraceptive health benefits.
        Am J Obstet Gynecol. 2011; 205: S4-S8
        • ACOG Committee on Practice Bulletins-Gynecology
        ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions.
        Obstet Gynecol. 2006; 107: 1453-1472
        • Helms S.E.
        • Bredle D.L.
        • Zajic J.
        • Jarjoura D.
        • Brodell R.T.
        • Krishnarao I.
        Oral contraceptive failure rates and oral antibiotics.
        J Am Acad Dermatol. 1997; 36: 705-710
        • London B.M.
        • Lookingbill D.P.
        Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives.
        Arch Dermatol. 1994; 130: 392-393
        • Krunic A.
        • Ciurea A.
        • Scheman A.
        Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone.
        J Am Acad Dermatol. 2008; 58: 60-62
        • Stewart F.H.
        • Harper C.C.
        • Ellertson C.E.
        • Grimes D.A.
        • Sawaya G.F.
        • Trussell J.
        Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence.
        JAMA. 2001; 285: 2232-2239
        • Cusan L.
        • Dupont A.
        • Gomez J.L.
        • Tremblay R.R.
        • Labrie F.
        Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial.
        Fertil Steril. 1994; 61: 281-287
        • Boisselle A.
        • Dionne F.T.
        • Tremblay R.R.
        Interaction of spironolactone with rat skin androgen receptor.
        Can J Biochem. 1979; 57: 1042-1046
        • Menard R.H.
        • Martin H.F.
        • Stripp B.
        • Gillette J.R.
        • Bartter F.C.
        Spironolactone and cytochrome P-450: impairment of steroid hydroxylation in the adrenal cortex.
        Life Sci. 1974; 15: 1639-1648
        • Menard R.H.
        • Stripp B.
        • Gillette J.R.
        Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism.
        Endocrinology. 1974; 94: 1628-1636
        • Rifka S.M.
        • Pita J.C.
        • Vigersky R.A.
        • Wilson Y.A.
        • Loriaux D.L.
        Interaction of digitalis and spironolactone with human sex steroid receptors.
        J Clin Endocrinol Metab. 1978; 46: 338-344
        • Zouboulis C.C.
        • Akamatsu H.
        • Stephanek K.
        • Orfanos C.E.
        Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone.
        Skin Pharmacol. 1994; 7: 33-40
        • Serafini P.C.
        • Catalino J.
        • Lobo R.A.
        The effect of spironolactone on genital skin 5 alpha-reductase activity.
        J Steroid Biochem. 1985; 23: 191-194
        • Muhlemann M.F.
        • Carter G.D.
        • Cream J.J.
        • Wise P.
        Oral spironolactone: an effective treatment for acne vulgaris in women.
        Br J Dermatol. 1986; 115: 227-232
        • Goodfellow A.
        • Alaghband-Zadeh J.
        • Carter G.
        • et al.
        Oral spironolactone improves acne vulgaris and reduces sebum excretion.
        Br J Dermatol. 1984; 111: 209-214
        • Brown J.
        • Farquhar C.
        • Lee O.
        • Toomath R.
        • Jepson R.G.
        Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
        Cochrane Database Syst Rev. 2009; : CD000194
        • Shaw J.C.
        • White L.E.
        Long-term safety of spironolactone in acne: results of an 8-year followup study.
        J Cutan Med Surg. 2002; 6: 541-545
        • Plovanich M.
        • Weng Q.Y.
        • Mostaghimi A.
        Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne.
        JAMA Dermatol. 2015; 151: 941-944
        • Zeichner J.A.
        Evaluating and treating the adult female patient with acne.
        J Drugs Dermatol. 2013; 12: 1416-1427
        • Loube S.D.
        • Quirk R.A.
        Letter: breast cancer associated with administration of spironolactone.
        Lancet. 1975; 1: 1428-1429
        • Danielson D.A.
        • Jick H.
        • Hunter J.R.
        • Stergachis A.
        • Madsen S.
        Nonestrogenic drugs and breast cancer.
        Am J Epidemiol. 1982; 116: 329-332
        • Friedman G.D.
        • Ury H.K.
        Initial screening for carcinogenicity of commonly used drugs.
        J Natl Cancer Inst. 1980; 65: 723-733
        • Mackenzie I.S.
        • Macdonald T.M.
        • Thompson A.
        • Morant S.
        • Wei L.
        Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.
        BMJ. 2012; 345: e4447
        • Biggar R.J.
        • Andersen E.W.
        • Wohlfahrt J.
        • Melbye M.
        Spironolactone use and the risk of breast and gynecologic cancers.
        Cancer Epidemiol. 2013; 37: 870-875
        • Cusan L.
        • Dupont A.
        • Belanger A.
        • Tremblay R.R.
        • Manhes G.
        • Labrie F.
        Treatment of hirsutism with the pure antiandrogen flutamide.
        J Am Acad Dermatol. 1990; 23: 462-469
        • Muderris II,
        • Bayram F.
        • Guven M.
        Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day).
        Gynecol Endocrinol. 2000; 14: 38-41
        • Carmina E.
        • Lobo R.A.
        A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women.
        Clin Endocrinol. 2002; 57: 231-234
        • Adalatkhah H.
        • Pourfarzi F.
        • Sadeghi-Bazargani H.
        Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial.
        Clin Cosmet Investig Dermatol. 2011; 4: 117-121
        • Calaf J.
        • Lopez E.
        • Millet A.
        • et al.
        Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial.
        J Clin Endocrinol Metab. 2007; 92: 3446-3452
        • Wysowski D.K.
        • Freiman J.P.
        • Tourtelot J.B.
        • Horton 3rd, M.L.
        Fatal and nonfatal hepatotoxicity associated with flutamide.
        Ann Intern Med. 1993; 118: 860-864
        • Garcia Cortes M.
        • Andrade R.J.
        • Lucena M.I.
        • et al.
        Flutamide-induced hepatotoxicity: report of a case series.
        Rev Esp Enferm Dig. 2001; 93: 423-432
        • Saihan E.M.
        • Burton J.L.
        Sebaceous gland suppression in female acne patients by combined glucocorticoid-oestrogen therapy.
        Br J Dermatol. 1980; 103: 139-142
        • Darley C.R.
        • Moore J.W.
        • Besser G.M.
        • Munro D.D.
        • Kirby J.D.
        Low dose prednisolone or oestrogen in the treatment of women with late onset or persistent acne vulgaris.
        Br J Dermatol. 1982; 108: 345-353
        • Jansen T.
        • Plewig G.
        Acne fulminans.
        Int J Dermatol. 1998; 37: 254-257
        • Karvonen S.L.
        Acne fulminans: report of clinical findings and treatment of twenty-four patients.
        J Am Acad Dermatol. 1993; 28: 572-579
        • Chivot M.
        • Midoun H.
        Isotretinoin and acne–a study of relapses.
        Dermatologica. 1990; 180: 240-243
        • Goulden V.
        • Clark S.M.
        • McGeown C.
        • Cunliffe W.J.
        Treatment of acne with intermittent isotretinoin.
        Br J Dermatol. 1997; 137: 106-108
        • King K.
        • Jones D.H.
        • Daltrey D.C.
        • Cunliffe W.J.
        A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population.
        Br J Dermatol. 1982; 107: 583-590
        • Lester R.S.
        • Schachter G.D.
        • Light M.J.
        Isotretinoin and tetracycline in the management of severe nodulocystic acne.
        Int J Dermatol. 1985; 24: 252-257
        • Blasiak R.C.
        • Stamey C.R.
        • Burkhart C.N.
        • Lugo-Somolinos A.
        • Morrell D.S.
        High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris.
        JAMA Dermatol. 2013; 149: 1392-1398
        • De D.
        • Kanwar A.J.
        Combination of low-dose isotretinoin and pulsed oral azithromycin in the management of moderate to severe acne: a preliminary open-label, prospective, non-comparative, single-centre study.
        Clin Drug Investig. 2011; 31: 599-604
        • Lee J.J.
        • Feng L.
        • Reshef D.S.
        • et al.
        Mortality in the randomized, controlled lung intergroup trial of isotretinoin.
        Cancer Prev Res (Phila). 2010; 3: 738-744
        • Bernstein C.N.
        • Nugent Z.
        • Longobardi T.
        • Blanchard J.F.
        Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study.
        Am J Gastroenterol. 2009; 104: 2774-2778
        • Dubeau M.F.
        • Iacucci M.
        • Beck P.L.
        • et al.
        Drug-induced inflammatory bowel disease and IBD-like conditions.
        Inflamm Bowel Dis. 2013; 19: 445-456
        • Rashtak S.
        • Khaleghi S.
        • Pittelkow M.R.
        • Larson J.J.
        • Lahr B.D.
        • Murray J.A.
        Isotretinoin exposure and risk of inflammatory bowel disease.
        JAMA Dermatol. 2014; 150: 1322-1326
      6. American Academy of Dermatology website. Position statement on isotretinoin. Available at: https://www.aad.org/Forms/Policies/Uploads/PS/PS-Isotretinoin.pdf. Accessed January 6, 2016.

        • Marqueling A.L.
        • Zane L.T.
        Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review.
        Semin Cutan Med Surg. 2005; 24: 92-102
        • Hull S.M.
        • Cunliffe W.J.
        • Hughes B.R.
        Treatment of the depressed and dysmorphophobic acne patient.
        Clin Exp Dermatol. 1991; 16: 210-211
        • Myhill J.E.
        • Leichtman S.R.
        • Burnett J.W.
        Self-esteem and social assertiveness in patients receiving isotretinoin treatment for cystic acne.
        Cutis. 1988; 41: 171-173
        • Ormerod A.D.
        • Thind C.K.
        • Rice S.A.
        • Reid I.C.
        • Williams J.H.
        • McCaffery P.J.
        Influence of isotretinoin on hippocampal-based learning in human subjects.
        Psychopharmacology. 2012; 221: 667-674
        • Luthi F.
        • Eggel Y.
        • Theumann N.
        Premature epiphyseal closure in an adolescent treated by retinoids for acne: an unusual cause of anterior knee pain.
        Joint Bone Spine. 2012; 79: 314-316
        • Steele R.G.
        • Lugg P.
        • Richardson M.
        Premature epiphyseal closure secondary to single-course vitamin A therapy.
        Aust N Z J Surg. 1999; 69: 825-827
        • Lammer E.J.
        • Chen D.T.
        • Hoar R.M.
        • et al.
        Retinoic acid embryopathy.
        N Engl J Med. 1985; 313: 837-841
        • McElwee N.E.
        • Schumacher M.C.
        • Johnson S.C.
        • et al.
        An observational study of isotretinoin recipients treated for acne in a health maintenance organization.
        Arch Dermatol. 1991; 127: 341-346
        • Rubenstein R.
        • Roenigk Jr., H.H.
        • Stegman S.J.
        • Hanke C.W.
        Atypical keloids after dermabrasion of patients taking isotretinoin.
        J Am Acad Dermatol. 1986; 15: 280-285
        • Zachariae H.
        Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment.
        Br J Dermatol. 1988; 118: 703-706
        • Bagatin E.
        • Parada M.O.
        • Miot H.A.
        • Hassun K.M.
        • Michalany N.
        • Talarico S.
        A randomized and controlled trial about the use of oral isotretinoin for photoaging.
        Int J Dermatol. 2010; 49: 207-214
        • Picosse F.R.
        • Yarak S.
        • Cabral N.C.
        • Bagatin E.
        Early chemabrasion for acne scars after treatment with oral isotretinoin.
        Dermatol Surg. 2012; 38: 1521-1526
        • Chandrashekar B.S.
        • Varsha D.V.
        • Vasanth V.
        • Jagadish P.
        • Madura C.
        • Rajashekar M.L.
        Safety of performing invasive acne scar treatment and laser hair removal in patients on oral isotretinoin: a retrospective study of 110 patients.
        Int J Dermatol. 2014; 53: 1281-1285
        • Kim H.W.
        • Chang S.E.
        • Kim J.E.
        • Ko J.Y.
        • Ro Y.S.
        The safe delivery of fractional ablative carbon dioxide laser treatment for acne scars in Asian patients receiving oral isotretinoin.
        Dermatol Surg. 2014; 40: 1361-1366
        • Yoon J.H.
        • Park E.J.
        • Kwon I.H.
        • et al.
        Concomitant use of an infrared fractional laser with low-dose isotretinoin for the treatment of acne and acne scars.
        J Dermatolog Treat. 2014; 25: 142-146
        • Basak P.Y.
        • Cetin E.S.
        • Gurses I.
        • Ozseven A.G.
        The effects of systemic isotretinoin and antibiotic therapy on the microbial floras in patients with acne vulgaris.
        J Eur Acad Dermatol Venereol. 2013; 27: 332-336
        • Williams R.E.
        • Doherty V.R.
        • Perkins W.
        • Aitchison T.C.
        • Mackie R.M.
        Staphylococcus aureus and intra-nasal mupirocin in patients receiving isotretinoin for acne.
        Br J Dermatol. 1992; 126: 362-366
        • Dai W.S.
        • LaBraico J.M.
        • Stern R.S.
        Epidemiology of isotretinoin exposure during pregnancy.
        J Am Acad Dermatol. 1992; 26: 599-606
        • Atzori L.
        • Brundu M.A.
        • Orru A.
        • Biggio P.
        Glycolic acid peeling in the treatment of acne.
        J Eur Acad Dermatol Venereol. 1999; 12: 119-122
        • Levesque A.
        • Hamzavi I.
        • Seite S.
        • Rougier A.
        • Bissonnette R.
        Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne.
        J Cosmet Dermatol. 2011; 10: 174-178
        • Pollock B.
        • Turner D.
        • Stringer M.R.
        • et al.
        Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action.
        Br J Dermatol. 2004; 151: 616-622
        • Gold M.H.
        • Bradshaw V.L.
        • Boring M.M.
        • Bridges T.M.
        • Biron J.A.
        • Carter L.N.
        The use of a novel intense pulsed light and heat source and ALA-PDT in the treatment of moderate to severe inflammatory acne vulgaris.
        J Drugs Dermatol. 2004; 3: S15-S19
        • Wang X.L.
        • Wang H.W.
        • Zhang L.L.
        • Guo M.X.
        • Huang Z.
        Topical ALA PDT for the treatment of severe acne vulgaris.
        Photodiagnosis Photodyn Ther. 2010; 7: 33-38
        • Ma L.
        • Xiang L.H.
        • Yu B.
        • et al.
        Low-dose topical 5-aminolevulinic acid photodynamic therapy in the treatment of different severity of acne vulgaris.
        Photodiagnosis Photodyn Ther. 2013; 10: 583-590
        • Lee S.J.
        • Hyun M.Y.
        • Park K.Y.
        • Kim B.J.
        A tip for performing intralesional triamcinolone acetonide injections in acne patients.
        J Am Acad Dermatol. 2014; 71: e127-e128
        • Kim K.S.
        • Kim Y.B.
        Anti-inflammatory effect of Keigai-rengyo-to extract and acupuncture in male patients with acne vulgaris: a randomized controlled pilot trial.
        J Altern Complement Med. 2012; 18: 501-508
        • Burris J.
        • Rietkerk W.
        • Woolf K.
        Relationships of self-reported dietary factors and perceived acne severity in a cohort of New York young adults.
        J Acad Nutr Diet. 2014; 114: 384-392
        • Adebamowo C.A.
        • Spiegelman D.
        • Danby F.W.
        • Frazier A.L.
        • Willett W.C.
        • Holmes M.D.
        High school dietary dairy intake and teenage acne.
        J Am Acad Dermatol. 2005; 52: 207-214
        • Sardana K.
        • Garg V.K.
        An observational study of methionine-bound zinc with antioxidants for mild to moderate acne vulgaris.
        Derm Ther. 2010; 23: 411-418
        • Jung G.W.
        • Tse J.E.
        • Guiha I.
        • Rao J.
        Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne.
        J Cutan Med Surg. 2013; 17: 114-122
        • Khayef G.
        • Young J.
        • Burns-Whitmore B.
        • Spalding T.
        Effects of fish oil supplementation on inflammatory acne.
        Lipids Health Dis. 2012; 11: 165

      Linked Article

      • Correction
        Journal of the American Academy of DermatologyVol. 82Issue 6
        • In Brief
          Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74:945–973.e33.
        • Full-Text
        • PDF